Navigation Links
New consensus reached to help tackle multidrug-resistant and extensively drug-resistant TB
Date:3/23/2014

New consensus statements have been developed to help tackle the growing threat of multidrug-resistant tuberculosis (TB) and extensively drug-resistant tuberculosis (TB).

Published online today (24 March 2014) in the European Respiratory Journal the statements mark the first time that physicians who treat patients with multidrug- and extensively drug-resistant TB have reached a consensus on important areas of patient management where scientific evidence is inconclusive.

The World Health Organization (WHO) estimates that currently 450,000 new cases with MDR-TB occur each year. The majority of affected patients live in the WHO European Region.

As the emergence of these forms of the disease is fairly recent, clinical evidence is lacking and could be for many years to come. To help bridge this gap in knowledge, experts from the European-based TBNET network have provided harmonised answers to the key questions for the prevention, diagnosis, treatment and management of multidrug- and extensively drug-resistant TB.

Although some guidelines are available for the treatment of people with multidrug- and extensively drug-resistant TB, this is the first time that a large group of predominantly clinical experts have joined together to provide a consensus on the management of these conditions in Europe.

The consensus statements also include useful checklists with information on which examinations should be performed during the course of the treatment and what is necessary before discharging a patient from the hospital. The authors suggest that the document can be used as a point of reference for physicians across the continent.

Lead author, Professor Christoph Lange, Head of the Respiratory Infections Assembly at the European Respiratory Society, said: "These consensus statements provide very valuable support for physicians treating patients with these deadly conditions in all parts of Europe. The current management of patients with multidrug- and extensively drug-resistant TB is complex, very costly for healthcare systems and burdensome for those who are affected.

"We have harmonised individual expert opinions on the management of multidrug- and extensively drug-resistant TB in adults and children to ensure that consensus is available where clinical evidence is still lacking. As clinicians we hope to improve the treatment of multidrug- and extensively drug-resistant TB and the life of our patients who suffer from these difficult-to-treat conditions."


'/>"/>

Contact: Lauren Anderson
lauren.anderson@europeanlung.org
0044-114-267-2876
European Lung Foundation
Source:Eurekalert  

Related medicine news :

1. GWU consensus report outlines new approaches for evaluating benefits and risks of obesity drugs
2. CRT consensus set to standardize and improve care for patients worldwide
3. IOM President to speak at Schwartz Center Consensus Meeting Nov. 8
4. JPIDS: Releases consensus statement on research definitions for drug-resistant TB in children
5. Hartford consensus aims to improve survival after mass shootings
6. Consensus statement on pediatric arrhythmias released by ESC and AEPC
7. Groundbreaking Consensus Statement Provides a Road Map for Treating Melanoma Patients with Cancer Immunotherapy
8. ASTRO and SSO issue consensus guideline on margins for breast-conserving surgery with WBI
9. Da Vinci Robotic Surgery Lawsuit News: Ohio Law Firm Investigates Da Vinci Robotic Surgery Complications as Settlement is Reached in Louisiana Da Vinci Robot Lawsuit
10. Cherry Creek Medical Weight Loss Has Reached Their Goal
11. ICREATE Technologies announces the new book Seven Symbiotic Collaborations For Spiritual Cashflow to have reached #19 in the Amazon.com bestseller list today morning
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New consensus reached to help tackle multidrug-resistant and extensively drug-resistant TB
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure today announced that ... donate to Give To Cure’s campaign that is crowdfunding clinical trials to help find ... share payments through a smart device. In 2015 alone, Venmo processed $7.5 billion in ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... At its ... of Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds ... of the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat ...
(Date:2/5/2016)... Francisco, CA (PRWEB) , ... February 05, 2016 ... ... and founder of CitiDent, announces that it is now welcoming orthodontist, ... Dr. Cheng, CitiDent offers a complete range of oral health care, including general ...
(Date:2/5/2016)... ... ... Health and wellness is a topic that should concern all Americans; however, it ... illness. Migraines are a severe form of a headache and often are accompanied by ... pain on their worst enemy, the feeling can last for many hours and be ...
(Date:2/5/2016)... ... February 05, 2016 , ... Calls Blacklist has just been ... user interface design and the developer has fixed known bugs within the app. Calls ... on their phone while not consuming any of their device’s battery power or memory. ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... LODI, N.J. , Feb. 4, 2016  Montoya ... Pinnacle Professional in the field of Pharmaceuticals. Montoya is ... . ... and supplies, Becton Dickinson provides healthcare institutions, ... medical equipment throughout fifty countries across the globe. ...
(Date:2/4/2016)... Feb. 4, 2016 Global Immunology Market ... to drive long-term market growth Summary ... of chronic disorders that affect 5–7% of western ... of their symptoms and key patient demographics, they ... immune pathways and an inappropriate immune response. Generally, ...
(Date:2/4/2016)... Calif., Feb. 4, 2016  Omnicell, Inc. (NASDAQ: OMCL ... solutions to healthcare systems, today announced results for its ... --> --> GAAP results: ... million, up $5.1 million or 4.1% from the third ... from the fourth quarter of 2014. Revenue for the ...
Breaking Medicine Technology: